Autism

Beyond Air® Announces Transition of Chief Financial Officer

Launched search for permanent successorGARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air”…

2 months ago

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related…

2 months ago

MIRDC Wins Dual R&D 100 Awards for AI-Guided Interactive Speech-Language Therapy System

KAOHSIUNG, Nov. 24, 2025 /PRNewswire/ -- The Metal Industries Research & Development Centre (MIRDC) has been awarded two 2025 R&D…

2 months ago

Main Line Psychiatric Practice Expands Comprehensive Mental Health Care for Autism and ADHD

Psychiatric Associates of Pennsylvania Addresses Critical Gap in Neurodevelopmental Mental Health Services NARBERTH, PA / ACCESS Newswire / November 24,…

2 months ago

Main Line Psychiatric Practice Expands Comprehensive Mental Health Care for Autism and ADHD

Psychiatric Associates of Pennsylvania Addresses Critical Gap in Neurodevelopmental Mental Health Services NARBERTH, PA / ACCESS Newswire / November 24,…

2 months ago

ADIA Nutrition Submits Patent-Pending Autism Protocol for Independent IRB Review – Clinical Study Launch Nears

Winter Park, Florida--(Newsfile Corp. - November 24, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA) announced today that, following the independent…

2 months ago

Oxford-Harrington Rare Disease Centre Announces 2025 Scholars Advancing Promising Treatments

Ten scientists selected for second annual award to pursue innovations in gene, RNA, small molecule and cell therapies to treat…

2 months ago

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors

BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development…

2 months ago

Artisan Therapeutics and Tulex Pharmaceuticals Announce Positive Phase 2a Results for ART-501, a Novel Oral Liquid Extended-Release Formulation for Autism Spectrum Disorder

Artisan and Tulex Report Positive Phase 2a Results for Autism Drug ART-501SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan…

2 months ago

RethinkBH and Raintree Debut Integrated Solution for Multidisciplinary Pediatric and Behavioral Health Practices

New collaboration enables users to streamline operations, reduce administrative burden and empower practices to expand into ABA services NEW YORK,…

2 months ago